Stock SUVENPHAR SUVEN PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Suven Pharmaceuticals Limited Bombay S.E.

Equities

SUVENPHAR

INE03QK01018

Market Closed - Bombay S.E.
Other stock markets
 06:00:49 2024-05-03 am EDT 		5-day change 1st Jan Change
671.2 INR +0.25% Intraday chart for Suven Pharmaceuticals Limited +2.02% -7.57%
Mar. 27 Suven Pharmaceuticals Limited Announces Shifting of Registered Office CI
Mar. 05 Transcript : Cohance Lifesciences Limited, Suven Pharmaceuticals Limited - M&A Call

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • With an expected P/E ratio at 42.01 and 51.11 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SUVEN PHARMACEUTICALS LIMITED Stock Suven Pharmaceuticals Limited
-7.57% 2.05B
D-
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
B-
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
B+
NOVARTIS AG Stock Novartis AG
+3.65% 198B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
A+
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
C+
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SUVENPHAR Stock
  4. SUVENPHAR Stock
  5. Ratings Suven Pharmaceuticals Limited